clopidogrel and cangrelor

clopidogrel has been researched along with cangrelor in 103 studies

Research

Studies (103)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's29 (28.16)29.6817
2010's68 (66.02)24.3611
2020's6 (5.83)2.80

Authors

AuthorsStudies
Chen, B; Danon, JJ; Kassiou, M; Ma, BB; Montgomery, AP1
Maayani, S; Martinez, R; Schwarz, T; Tagliente, TM1
Guile, SD; Ince, F; Ingall, AH; Kindon, ND; Meghani, P; Mortimore, MP1
Heptinstall, S; Judge, HM; Storey, RF; Wilcox, RG1
Heptinstall, S; Storey, RF; Wilcox, RG1
Heemskerk, JW; Heijnen, VV; oude Egbrink, MG; Reneman, RS; Slaaf, DW; van Gestel, MA1
Behan, MW; Fox, SC; Heptinstall, S1
Aleil, B; Cazenave, JP; Gachet, C; Heitz, A; Ravanat, C; Rochoux, G1
Boeynaems, JM; Herbert, JM; Savi, P; van Giezen, H1
Behan, MW; Fox, SC; Heptinstall, S; Storey, RF1
Graff, J; Harder, S1
Garcia, A; Kim, S; Kunapuli, SP; Prabhakar, J; Shankar, H1
Harrison, P; Pidcock, M1
Gurbel, PA; Tantry, US1
Cattaneo, M2
Akers, WS; Charnigo, R; Ferraris, S; Oestreich, JH; Oh, JJ; Steinhubl, SR1
Angiolillo, DJ1
Buckland, RJ; Jakubowski, JA; Judge, HM; Storey, RF; Sugidachi, A1
Inoue, K; Kohsaka, S; Miyata, H; Tozaki-Saitoh, H; Tsuda, M; Ueda, K1
Dovlatova, NL; Heptinstall, S; Jakubowski, JA; Sugidachi, A1
Dovlatova, N; Heptinstall, S; Johnson, A1
Barker, CM; Price, MJ1
Eikelboom, JW; Hirsh, J; Raju, NC1
Béres, BJ; Kerecsen, G; Kiss, RG; László, A; Masszi, T; Préda, I; Tóth-Zsámboki, E; Vargová, K1
Akram, F; Akram, S; Postuła, M1
Butt, M; Lip, GY; Shantsila, E; Siddique, A1
Fox, SC; Heptinstall, S; May, JA; Neubert, U; Shah, A1
Amine, M; Angiolillo, DJ; Becker, RC; Bhatt, DL; Chew, DP; French, WJ; Gibson, CM; Goodman, SG; Harrington, RA; Kleiman, NS; Leisch, F; Lincoff, AM; Mahaffey, KW; McNulty, S; Montalescot, G; Parikh, KH; Pollack, CV; Skerjanec, S; Stone, GW; White, HD1
Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J1
del Río, A; Heras, M1
Jilma, B; Krumphuber, J; Siller-Matula, JM1
Brunner, KP; Kobsar, AL; Koessler, J; Rajkovic, MS; Steigerwald, U; Walter, U1
Cattaneo, M; Podda, GM1
Faxon, DP1
Ruparelia, N; Spyrou, N1
Favaloro, EJ; Franchini, M; Lippi, G1
Bauersachs, J; Flierl, U; Kobsar, AL; Koessler, J; Pfoertsch, S; Rajkovic, MS; Rechner, AR; Schafer, A; Steigerwald, U; Walter, U1
Frey, N; Ivandic, B1
Ağırbaşlı, M; Cinçin, A; Güvenç, H1
Akers, WS; Ferraris, SP; Oestreich, JH; Steinhubl, SR1
Storey, RF2
Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J1
Chiżyński, K; Golański, J; Kuliczkowski, W; Rychlik, B; Watała, C1
Cattaneo, GJ; Cattaneo, M; Podda, GM1
Moliterno, DJ; Rajan, L1
Caglayan, E; Er, F; Erdmann, E; Gassanov, N1
Contractor, H; Ruparelia, N1
Lavi, R; Lavi, S1
Angiolillo, DJ; Becker, RC; Bhatt, DL; French, WJ; Harrington, RA; Huber, K; Liu, T; Prats, J; Price, MJ; Saucedo, JF; Schneider, DJ; Shaburishvili, T1
Bhatt, DL; Dietrich, M; Gallup, D; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; Price, MJ; Skerjanec, S; Steg, GW; Stone, GW; Todd, M; White, HD1
Barn, K; Steinhubl, SR1
Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J1
Bernlochner, I; Sibbing, D1
Cohen, MV; Cui, L; Downey, JM; Kambayashi, J; Liu, Y; Tandon, N; Yang, X; Yang, XM1
Angiolillo, DJ; Bhatt, DL; Bramucci, E; Gallup, D; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; McLaurin, BT; Prats, J; Price, MJ; Radke, PW; Skerjanec, S; Spriggs, D; Steg, PG; Stone, GW; Tauth, J; Todd, M; Tousek, F; White, HD; Widimský, P1
Hillis, LD; Lange, RA1
Aylward, PE; Sinhal, AR1
Aryal Pandit, A; Aryal, MR; Hakim, FA; Jalota, L; Lee, HR; Mookadam, F; Pandit, A; Tleyjeh, IM1
Limbruno, U; Musumeci, G1
Angiolillo, DJ; Bhatt, DL; Brener, SJ; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; LaSalle, L; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Skerjanec, S; Steg, PG; Stone, GW; Todd, M; White, HD1
DiNicolantonio, JJ; Serebruany, VL; Sibbing, D1
DiNicolantonio, JJ; Fortmann, SD; Pokov, AN; Serebruany, VL1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ1
Sabouret, P; Taiel-Sartral, M1
Caldeira, D; Ferreira, JJ; Pinto, FJ1
Adamski, P; Fabiszak, T; Grześk, G; Koziński, M; Kubica, J; Navarese, EP; Ostrowska, M; Paciorek, P1
Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M1
Buckland, RJ; Jakubowski, JA; Judge, HM; Storey, RF1
Agarwal, Z; Gogo, P; Schneider, DJ; Seecheran, N1
Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD1
Bolek, T; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M1
Basabe-Desmonts, L; Gilmartin, N; Jose, B; Kenny, D; Kent, NJ; McCluskey, P; Ricco, AJ; Somers, M1
Angiolillo, DJ; Capodanno, D1
Cahoon, WD; Francis, KE; Lowe, DK; Magee, LC; Oswalt, AK1
Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD2
Sinha, A; Storey, RF1
Bhatt, DL; Cavender, MA; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD1
Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD1
Bhatt, DL; Deliargyris, EN; Elkin, S; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Menozzi, A; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD1
Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD1
Lipinski, MJ; Torguson, R; Waksman, R; Westman, PC1
Amann, M; Bömicke, T; Ferenc, M; Hauschke, D; Hochholzer, W; Kleiner, P; Löffelhardt, N; Neumann, FJ; Stratz, C; Trenk, D; Valina, CM; Younas, I1
Bhatt, DL; Day, JRS; Gibson, CM; Hamm, CW; Mahaffey, KW; Parker, WA; Prats, J; Price, MJ; Steg, PG; Stone, GW; Storey, RF; White, HD1
Abnousi, F; Bhatt, DL; Deliargyris, EN; Desai, M; Ding, VY; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Sundaram, V; White, HD; Yang, L; Yong, CM1
Bhatt, DL; Deliargyris, EN; Eisen, A; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD1
Alexopoulos, D; Lekakis, J; Pappas, C; Sfantou, D1
Ferenc, M; Hochholzer, W; Löffelhardt, N; Mashayekhi, K; Neumann, FJ; Nührenberg, T; Stratz, C; Trenk, D; Valina, CM1
Angiolillo, DJ; Bhatt, DL; Deliargyris, EN; Gibson, CM; Groves, EM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD1
Amin, AP; Bhatt, DL; Fan, W; Généreux, P; Gibson, CM; Harrington, RA; Kirtane, AJ; Pinto, DS; Stone, GW; Tamez, H; White, HD; Yeh, RW1
Calnan, MW; Crawford, AN1
Bhatt, DL; Deliargyris, EN; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD1
Farag, M; Gorog, DA; Gue, YX; Spinthakis, N; Srinivasan, M; Wellsted, DM1
Banerjee, S; Baskar, A; Chauhan, S; Cui, Z; Dargham, BB; Sum-Ping, J; Tejani, I; Weideman, RA1
Abtan, J; Bhatt, DL; Deliargyris, EN; Ducrocq, G; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD1
Capodanno, D; Capranzano, P1
Dabus, G; Linfante, I; Ravipati, K; Reyes, D; Starosciak, AK1
Ishigaku, Y; Itabashi, R; Kamada, A; Maeda, T; Narumi, S; Natori, T; Oi, K; Oura, K; Shimizu, M; Terayama, Y; Tsuda, K; Yoshida, M1
Bhatt, DL; Cavender, MA; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Lopes, RD; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD1
Angiolillo, DJ; Bhatt, DL; Davidson-Ray, L; Dell'Anna, C; Diaz, M; Edwards, L; El-Sabae, H; Garratt, KN; Ohman, EM; Rymer, JA; Salahuddin, K; Tasissa, G; Waksman, R; Wang, TY; Washam, JB1

Reviews

38 review(s) available for clopidogrel and cangrelor

ArticleYear
Strategies for targeting the P2Y
    Bioorganic & medicinal chemistry letters, 2022, 09-01, Volume: 71

    Topics: Central Nervous System; Ligands; Microglia; Platelet Aggregation; Receptors, Purinergic P2Y12; Signal Transduction

2022
The medicinal chemistry of the P2 receptor family.
    Progress in medicinal chemistry, 2001, Volume: 38

    Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Arteriosclerosis; Cloning, Molecular; Clopidogrel; Cystic Fibrosis; Humans; Ophthalmic Solutions; Polyphosphates; Receptors, Purinergic P2; Structure-Activity Relationship; Ticlopidine; Tissue Distribution; Uracil Nucleotides

2001
P2Y receptor antagonists in thrombosis.
    Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:3

    Topics: Adenosine Monophosphate; Animals; Clopidogrel; Humans; Mice; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Thrombosis; Ticlopidine

2005
Aspirin and clopidogrel resistance: consideration and management.
    Journal of interventional cardiology, 2006, Volume: 19, Issue:5

    Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine

2006
Platelet P2 receptors: old and new targets for antithrombotic drugs.
    Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:1

    Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine

2007
ADP receptor antagonism: what's in the pipeline?
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007, Volume: 7, Issue:6

    Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2007
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
    Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:12

    Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2008
Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.
    Recent patents on cardiovascular drug discovery, 2009, Volume: 4, Issue:1

    Topics: Adenosine; Adenosine Monophosphate; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Imines; Lactones; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine

2009
New antiplatelet drugs: beyond aspirin and clopidogrel.
    International journal of clinical practice, 2009, Volume: 63, Issue:5

    Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine

2009
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine

2009
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9 Suppl 1

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine

2009
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
    British journal of pharmacology, 2010, Feb-01, Volume: 159, Issue:3

    Topics: Adenosine; Adenosine Monophosphate; Benzofurans; Blood Platelets; Carbamates; Clinical Trials as Topic; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Receptor, PAR-1; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Ticlopidine; von Willebrand Factor

2010
State of the art of new P2Y12 antagonists.
    Internal and emergency medicine, 2010, Volume: 5, Issue:5

    Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine

2010
[New approaches and indications for the analysis of platelet function in cardiology].
    Hamostaseologie, 2011, May-02, Volume: 31, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine

2011
[Novel agents in antiplatelet therapy].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2010, Volume: 38, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine

2010
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
    Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1

    Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine

2011
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
    Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1

    Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2011
[Myocardial infarction: Role of new antiplatelet agents].
    Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:6

    Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors

2011
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
    Recenti progressi in medicina, 2011, Volume: 102, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine

2011
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
    Current cardiology reports, 2011, Volume: 13, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine

2011
[ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:27

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Pyridines; Receptors, Purinergic P2; Stents; Ticlopidine

2011
Advances in antiplatelet therapy for acute coronary syndromes.
    Postgraduate medical journal, 2012, Volume: 88, Issue:1041

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2012
Perioperative management of antiplatelet agents in patients undergoing cardiac surgery.
    Journal of cardiothoracic and vascular anesthesia, 2012, Volume: 26, Issue:4

    Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticagrelor; Ticlopidine

2012
A brief review of the past and future of platelet P2Y12 antagonist.
    Coronary artery disease, 2012, Volume: 23, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2012
Thienopyridines and other ADP-receptor antagonists.
    Handbook of experimental pharmacology, 2012, Issue:210

    Topics: Adenosine; Adenosine Monophosphate; Animals; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine

2012
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
    Clinical therapeutics, 2013, Volume: 35, Issue:8

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2013
Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Mar-20, Volume: 9, Issue:11

    Topics: Adenosine Monophosphate; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Thrombosis; Ticlopidine

2014
Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
    Cardiology, 2014, Volume: 127, Issue:1

    Topics: Acute Lung Injury; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Sulfonamides; Ticagrelor; Ticlopidine; Transfusion Reaction

2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Atherosclerosis, 2014, Volume: 233, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine

2014
New antiplatelet agents in the treatment of acute coronary syndromes.
    Archives of cardiovascular diseases, 2014, Volume: 107, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2014
Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:4

    Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Dyspnea; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine

2014
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:2

    Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Off-Label Use; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2014
Type 2 Diabetes and ADP Receptor Blocker Therapy.
    Journal of diabetes research, 2016, Volume: 2016

    Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome

2016
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.
    Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:7

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine

2016
Cangrelor for the management and prevention of arterial thrombosis.
    Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:9

    Topics: Adenosine Monophosphate; Administration, Intravenous; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticlopidine

2016
A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Cardiovascular revascularization medicine : including molecular interventions, 2017, Volume: 18, Issue:2

    Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome

2017
Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
    Journal of cardiovascular pharmacology and therapeutics, 2018, Volume: 23, Issue:1

    Topics: Adenosine Monophosphate; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine

2018
Switching between P2Y
    Vascular pharmacology, 2019, Volume: 116

    Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Blood Platelets; Cardiovascular Diseases; Clinical Decision-Making; Clopidogrel; Drug Substitution; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Treatment Outcome

2019

Trials

23 trial(s) available for clopidogrel and cangrelor

ArticleYear
Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
    Platelets, 2002, Volume: 13, Issue:7

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Ticlopidine

2002
Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect.
    Thrombosis research, 2008, Volume: 121, Issue:4

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adolescent; Adult; Clopidogrel; Cyclooxygenase Inhibitors; Female; Humans; Male; Middle Aged; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine

2008
Platelet inhibition with cangrelor in patients undergoing PCI.
    The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Ticlopidine; Treatment Failure

2009
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
    Journal of thrombosis and thrombolysis, 2012, Volume: 34, Issue:1

    Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Antagonism; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Preoperative Care; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine

2012
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
    American heart journal, 2012, Volume: 163, Issue:5

    Topics: Adenosine Monophosphate; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Survival Analysis; Ticlopidine; Treatment Outcome

2012
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
    The New England journal of medicine, 2013, Apr-04, Volume: 368, Issue:14

    Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine

2013
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Interv
    Journal of the American College of Cardiology, 2014, Feb-25, Volume: 63, Issue:7

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Intraoperative Complications; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Standard of Care; Stents; Thrombosis; Ticlopidine; Treatment Outcome

2014
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:3

    Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recombinant Proteins; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome

2015
Pharmacodynamic Effects When Clopidogrel is Given Before Cangrelor Discontinuation.
    Journal of interventional cardiology, 2015, Volume: 28, Issue:5

    Topics: Adenosine Monophosphate; Adult; Aged; Biological Availability; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine

2015
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
    European heart journal, 2016, Apr-07, Volume: 37, Issue:14

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Femoral Artery; Graft Occlusion, Vascular; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Radial Artery; Stents; Ticlopidine; Treatment Outcome

2016
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
    Circulation. Cardiovascular interventions, 2016, Volume: 9, Issue:6

    Topics: Adenosine Monophosphate; Aged; Brazil; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Europe; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; New Zealand; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Thailand; Ticlopidine; Time Factors; Treatment Outcome; United States

2016
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
    Circulation, 2016, Sep-06, Volume: 134, Issue:10

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Disease Management; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine

2016
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    JACC. Cardiovascular interventions, 2016, 09-26, Volume: 9, Issue:18

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome

2016
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
    JAMA cardiology, 2017, 02-01, Volume: 2, Issue:2

    Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Survival Rate; Treatment Outcome; United States

2017
Randomized Comparison of Oral P2Y
    JACC. Cardiovascular interventions, 2017, 01-23, Volume: 10, Issue:2

    Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Disease; Drug Substitution; Female; Germany; Humans; Infusions, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome

2017
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Percutaneous Coronary Intervention; Receptors, Purinergic P2Y12; Survival Analysis; Ticlopidine; Treatment Outcome; Withholding Treatment

2017
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
    American heart journal, 2017, Volume: 188

    Topics: Adenosine Monophosphate; Administration, Oral; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Global Health; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Survival Rate; Ticlopidine; Time Factors

2017
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX).
    The American journal of cardiology, 2017, Oct-01, Volume: 120, Issue:7

    Topics: Adenosine Monophosphate; Aged; Anticoagulants; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heparin; Humans; Intraoperative Period; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Retrospective Studies; Ticlopidine; Treatment Outcome

2017
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials.
    International journal of cardiology, 2018, Jan-01, Volume: 250

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome

2018
Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
    Thrombosis and haemostasis, 2018, Volume: 118, Issue:2

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Ticagrelor

2018
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2018, 11-01, Volume: 92, Issue:5

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Female; Hemorrhage; Hospital Costs; Hospital Mortality; Humans; Length of Stay; Male; Middle Aged; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Time Factors; Treatment Outcome; United States

2018
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPIO
    European heart journal, 2018, 12-07, Volume: 39, Issue:46

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Perioperative Care; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; United States

2018
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
    Circulation. Cardiovascular interventions, 2022, Volume: 15, Issue:1

    Topics: Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Treatment Outcome

2022

Other Studies

42 other study(ies) available for clopidogrel and cangrelor

ArticleYear
Activation of Gi-coupled receptors releases a tonic state of inhibited platelet aggregation.
    Platelets, 2001, Volume: 12, Issue:2

    Topics: Adaptation, Physiological; Adenosine Diphosphate; Adenosine Monophosphate; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; Clopidogrel; Epinephrine; Female; GTP-Binding Protein alpha Subunits, Gi-Go; GTP-Binding Protein alpha Subunits, Gq-G11; Heterotrimeric GTP-Binding Proteins; Hirudins; Humans; Male; Membrane Proteins; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Agonists; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-2; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Receptors, Serotonin; Recombinant Proteins; Serotonin; Serotonin Receptor Agonists; Ticlopidine

2001
Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.
    Thrombosis and haemostasis, 2002, Volume: 88, Issue:3

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aspirin; Blood Platelets; Cell Adhesion; Clopidogrel; Drug Therapy, Combination; Female; Humans; Leukocytes; Male; Membrane Proteins; Middle Aged; Myocardial Ischemia; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Ticlopidine

2002
In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability.
    Arteriosclerosis, thrombosis, and vascular biology, 2003, Mar-01, Volume: 23, Issue:3

    Topics: Adenosine Monophosphate; Administration, Oral; Animals; Blood Platelets; Calcium; Clopidogrel; Female; Male; Membrane Proteins; Platelet Activation; Platelet Aggregation; Purinergic P2 Receptor Antagonists; Rabbits; Receptors, Purinergic P2Y12; Thrombin; Thromboembolism; Ticlopidine

2003
Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1.
    Cell calcium, 2004, Volume: 35, Issue:1

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Alprostadil; Calcium; Calcium Signaling; Clopidogrel; Cytoplasm; Dose-Response Relationship, Drug; Drug Synergism; Humans; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Time Factors

2004
Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:1

    Topics: Actins; Adenosine Diphosphate; Adenosine Monophosphate; Adult; Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relationship, Drug; Drug Resistance; Female; Flow Cytometry; Humans; Male; Membrane Proteins; Microfilament Proteins; Middle Aged; Myocardial Ischemia; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Time Factors

2005
Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
    Platelets, 2005, Volume: 16, Issue:2

    Topics: Adenosine Monophosphate; Calcium Signaling; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Female; Humans; Male; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Receptors, Thrombin; Ticlopidine

2005
Investigation of the PADA as a method for monitoring GPIIb/IIIa inhibitors and other antiplatelet agents.
    Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:4

    Topics: Abciximab; Adenosine Monophosphate; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Monitoring; Eptifibatide; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Sensitivity and Specificity; Ticlopidine

2005
P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation.
    Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:3

    Topics: Adenosine Monophosphate; Animals; Blood Platelets; Butadienes; Clopidogrel; Enzyme Inhibitors; Humans; Membrane Proteins; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Nitriles; Phospholipases A; Phospholipases A2; Platelet Aggregation Inhibitors; Pyrimidines; Receptor, PAR-1; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Receptors, Thrombin; Signal Transduction; src-Family Kinases; Thrombin; Thromboxane A2; Ticlopidine

2006
Can the PFA-100 be modified to detect P2Y12 inhibition?
    Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:6

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Monitoring; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Ticlopidine

2006
The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
    Platelets, 2008, Volume: 19, Issue:2

    Topics: Adenosine Monophosphate; Adult; Annexin A5; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytoplasmic Granules; Humans; In Vitro Techniques; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2008
P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008, May-07, Volume: 28, Issue:19

    Topics: Adenosine Monophosphate; Administration, Oral; Animals; Clopidogrel; Hyperesthesia; Injections, Spinal; Male; Membrane Proteins; Mice; Mice, Knockout; Microglia; Neuralgia; Purinergic P2 Receptor Antagonists; Rats; Rats, Wistar; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Spinal Cord; Spinal Nerves; Ticlopidine; Up-Regulation

2008
The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
    Journal of thrombosis and haemostasis : JTH, 2008, Volume: 6, Issue:7

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cells, Cultured; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2008
Multiple electrode aggregometry and P2Y(12) antagonists.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:6

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Anticoagulants; Clopidogrel; Dose-Response Relationship, Drug; Electrodes; Equipment Design; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine

2008
Antiplatelet therapy in acute coronary syndromes.
    Current cardiology reports, 2008, Volume: 10, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine

2008
Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:5

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adrenergic alpha-Antagonists; Aged; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Norepinephrine; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptors, Adrenergic, alpha-2; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Failure

2008
Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin.
    Platelets, 2009, Volume: 20, Issue:4

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aspirin; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Drug Monitoring; Female; Flow Cytometry; Humans; Male; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Tissue Fixation

2009
Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.
    Platelets, 2010, Volume: 21, Issue:2

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adult; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Flow Cytometry; Humans; Iloprost; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Epoprostenol; Receptors, Purinergic P2Y12; Ticlopidine; Young Adult

2010
Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.
    Nature reviews. Cardiology, 2010, Volume: 7, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thrombosis; Ticlopidine; Treatment Outcome

2010
Platelet inhibition with cangrelor.
    The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11

    Topics: Adenosine Monophosphate; Administration, Oral; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Infusions, Intravenous; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine

2010
Platelet inhibition with cangrelor.
    The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11

    Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Research Design; Ticlopidine

2010
The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
    Platelets, 2011, Volume: 22, Issue:1

    Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Biological Assay; Biomarkers; Blood Platelets; Case-Control Studies; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Sensitivity and Specificity; Ticlopidine; Young Adult

2011
High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the double-standard dose in an assay-dependent manner.
    Thrombosis and haemostasis, 2011, Volume: 105, Issue:5

    Topics: Adenosine Monophosphate; Aged; Angioplasty; Clinical Protocols; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Function Tests; Predictive Value of Tests; Reproducibility of Results; Thrombolytic Therapy; Ticlopidine; Treatment Outcome

2011
Comparison of the VASP assay and platelet aggregometry in the evaluation of platelet P2Y12 receptor blockade.
    Polskie Archiwum Medycyny Wewnetrznej, 2011, Volume: 121, Issue:4

    Topics: Adenosine Monophosphate; Adult; Aged; Cell Adhesion Molecules; Clopidogrel; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Function Tests; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine

2011
Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
    Thrombosis research, 2012, Volume: 130, Issue:4

    Topics: Adenosine; Adenosine Monophosphate; Animals; Blood Platelets; Clopidogrel; Dogs; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine

2012
Platelet P2Y₁₂ blockers confer direct postconditioning-like protection in reperfused rabbit hearts.
    Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:3

    Topics: Adenosine Monophosphate; Animals; Cardiotonic Agents; Clopidogrel; Coronary Vessels; Female; Heart; In Vitro Techniques; Ischemic Postconditioning; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Perfusion; Platelet Activation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Purinergic P2Y Receptor Antagonists; Rabbits; Receptors, Purinergic P2Y12; Signal Transduction; Ticlopidine

2013
The duel between dual antiplatelet therapies.
    The New England journal of medicine, 2013, Apr-04, Volume: 368, Issue:14

    Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine

2013
Antiplatelet therapy. Cangrelor succeeds, at last, in PCI.
    Nature reviews. Cardiology, 2013, Volume: 10, Issue:6

    Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Blood Platelets; Clopidogrel; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Outcome

2013
[The CHAMPION PHOENIX study].
    Giornale italiano di cardiologia (2006), 2013, Volume: 14, Issue:10

    Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Double-Blind Method; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Ticlopidine

2013
Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge.
    Thrombosis and haemostasis, 2014, Volume: 111, Issue:1

    Topics: Adenosine Monophosphate; Blood Platelets; Clopidogrel; Data Interpretation, Statistical; Humans; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome

2014
Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
    Platelets, 2016, Volume: 27, Issue:3

    Topics: Adenosine Monophosphate; Binding, Competitive; Clopidogrel; Humans; In Vitro Techniques; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine

2016
Self-Powered Microfluidic Device for Rapid Assay of Antiplatelet Drugs.
    Langmuir : the ACS journal of surfaces and colloids, 2016, Mar-22, Volume: 32, Issue:11

    Topics: Abciximab; Adenosine; Adenosine Monophosphate; Animals; Antibodies, Monoclonal; Cattle; Clopidogrel; Dimethylpolysiloxanes; Equipment Design; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Lab-On-A-Chip Devices; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Powders; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Serum Albumin, Bovine; Ticagrelor; Ticlopidine

2016
Cangrelor Bridge Therapy for Gastroduodenal Biopsy.
    Journal of pharmacy practice, 2017, Volume: 30, Issue:2

    Topics: Adenosine Monophosphate; Administration, Intravenous; Biopsy; Clopidogrel; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine

2017
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
    Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:1

    Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome

2017
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
    Circulation. Cardiovascular interventions, 2018, Volume: 11, Issue:4

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thrombocytopenia; Time Factors; Treatment Outcome

2018
A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy.
    Journal of pharmacy practice, 2020, Volume: 33, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Aspirin; Biopsy; Bronchoscopy; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor

2020
Effect of P2Y
    Thrombosis research, 2019, Volume: 173

    Topics: Adenosine Monophosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Fibrin Clot Lysis Time; Fibrinolysis; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor

2019
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
    Cardiovascular revascularization medicine : including molecular interventions, 2019, Volume: 20, Issue:9

    Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome

2019
intravenous cangrelor (Kengrexal°) and coronary angioplasty: No advantage over first-line clopidogrel.
    Prescrire international, 2016, Volume: 25, Issue:175

    Topics: Adenosine Monophosphate; Administration, Intravenous; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome

2016
Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
    Circulation. Cardiovascular interventions, 2019, Volume: 12, Issue:3

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Stents; Time Factors; Treatment Outcome

2019
Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention.
    Journal of neurointerventional surgery, 2021, Volume: 13, Issue:1

    Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Clopidogrel; Endovascular Procedures; Female; Humans; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Self Expandable Metallic Stents; Stroke; Subarachnoid Hemorrhage; Ticagrelor; Treatment Outcome

2021
Inhibitory Effects of P2Y12 Receptor Antagonist on PAR1- and PAR4-AP-Induced Platelet Aggregation in Patients with Stroke or TIA.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2021, Volume: 30, Issue:3

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Ischemic Stroke; Male; Middle Aged; Oligopeptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Treatment Outcome

2021
Cangrelor Use Patterns and Transition to Oral P2Y
    Journal of the American Heart Association, 2022, 06-07, Volume: 11, Issue:11

    Topics: Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Treatment Outcome

2022